<code id='3E14CC99E2'></code><style id='3E14CC99E2'></style>
    • <acronym id='3E14CC99E2'></acronym>
      <center id='3E14CC99E2'><center id='3E14CC99E2'><tfoot id='3E14CC99E2'></tfoot></center><abbr id='3E14CC99E2'><dir id='3E14CC99E2'><tfoot id='3E14CC99E2'></tfoot><noframes id='3E14CC99E2'>

    • <optgroup id='3E14CC99E2'><strike id='3E14CC99E2'><sup id='3E14CC99E2'></sup></strike><code id='3E14CC99E2'></code></optgroup>
        1. <b id='3E14CC99E2'><label id='3E14CC99E2'><select id='3E14CC99E2'><dt id='3E14CC99E2'><span id='3E14CC99E2'></span></dt></select></label></b><u id='3E14CC99E2'></u>
          <i id='3E14CC99E2'><strike id='3E14CC99E2'><tt id='3E14CC99E2'><pre id='3E14CC99E2'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:1984
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          Analysis of telehealth claims data suggest service duplication
          Analysis of telehealth claims data suggest service duplication

          AdobeYou’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechistransformingthelifesc

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          Stroke deaths set to near 10 million globally by 2050

          AdobeThenumberofstrokedeathsworldwideissettoclimb50%tonearly10millionby2050,withmostcasesoccurringin